INTRODUCTION
Statins are the most commonly used drugs for treatment of hypercholesterolemia. They had become a first choice in current prescribing practice and are pivotal in the primary and secondary prevention of cardiovascular disease (Hindler et al., 2006; Vrecer et al., 2003) . The discovery of statins significantly changed the approach to dislipidemic therapy and tremendously decreased morbidity and mortality from cardiovascular events by 50% (Fox et al., 2007) . Statins are generally well tolerated drugs and this is one of the reasons why they replaced previous drugs used to reduce cardiovascular events. However there are few side effects of statins that are monitored and reported. Statins can increase activity in hepatic transaminases in up to 5% of patients; this effect is dose-related. Adverse effects associated with treatment of statins are myotoxicity, including myopathy and rhabdomyolysis, what led to acute renal insufficiency, however with low incidence (0.1 %) (Bays, 2006) .
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. This enzyme is a rate limiting step in cholesterol biosynthesis in the liver. As an essential step in biosynthesis of mevalonate pathway statins affect levels of cholesterol and other downstream products (isoprenoids) important in many physiological processes such as cell signalling, apoptosis, protein synthesis, cell growth, posttranslational modifications and differentiation. Changes of these processes in neoplastic cells may therefore result in the control of tumor initiation, growth, and metastasis by statins (Chan et al., 2003 Although the favourable effects of statins in the prevention of cardiovascular diseases resulting from hypercholesterolemia are well established, the increasing evidence suggests that these drugs exert pleiotropic effects, independent of cholesterol reduction. Our previous study with atorvastatin and rosuvastatin pointed to fact that the antineoplastic effect of these drugs in rat mammary carcinogenesis is independent from its effects on plasma lipid metabolism (Kubatka et al., 2011a,b) . Rats are commonly used animals in cancer protective studies (Kubatka et al., 2011a,b; Popov et al., 1996; Radojicic et al., 2002) and also in other experimental approaches (Zorica et al., 2008; Djelic et al., 1999) . On the other hand, some studies described unresponsiveness of rats to different statins within hypocholesterolemic treatment (Krause et Princen, 1998) .
The aim of this study was to evaluate the effect of dietary administered fluvastatin on serum levels of triacylglycerols, total cholesterol, and LDL-, HDL-, VLDL-cholesterol in a well-established model of breast carcinoma in rats.
MATERIAL AND METHODS

Animals
Female rats of Sprague-Dawley strain (Charles River Laboratories, Sulzfeld, Germany) aged 32-36 days were used in the experiment. The animals were adapted to standard vivarium conditions with ambient temperature 23±2 In the last -17 th week of the experiment, the animals were decapitated, the blood from each animal was collected, mammary tumors were excised and tumor size recorded. Macroscopic changes in the selected organs (liver, spleen, kidney, stomach, intestine, and lung) were evaluated at autopsy. The tumors were classified according to the criteria for the classification of rat mammary tumors. Serum lipid parameters -triacylglycerols, total cholesterol, cholesterol of low density-, very low density-, and high density lipoprotein (LDL, VLDL, HDL) fractions were evaluated by automatic biochemical analyser Olympus AU640 (Olympus Optical, Tokyo, Japan).
Statistical analysis
Kruskal-Wallis test and one-way analysis of variance were statistical methods used for data evaluation in this experiment.
RESULTS
This study is a follow-up of our previous paper where the significant tumorpreventive effect of fluvastatin in rat mammary carcinogenesis was recorded (Kubatka et al., in press ). Fluvastatin in animals treated with both lower and higher doses apparently increased serum levels of triacylglycerols, total cholesterol, and LDL-, HDL-, VLDL-cholesterol when compared to the control group (Table 1) Highly significant body mass gain decrease in rats treated with fluvastatin was not accompanied by an apparent decrease in food intake in these animals. Slight decrease in food consumption when compared to control animals was observed only in FLUVA 20 group (P=0.037). Food and water intake by animals from all experimental groups is summarised in Table 2 . 
DISCUSSION
Although the favourable effects of statins in the prevention of cardiovascular diseases resulting from hypercholesterolemia are generally known, the increasing evidence suggests that these drugs exert pleiotropic effects, independent of cholesterol reduction. Fluvastatin in our experiment revealed apparent tumor-suppressive effects in rat mammary carcinogenesis (Kubatka et al., in press), however significant detrimental effects on plasma lipids were recorded. Our previous study with dietary administered atorvastatin (10 and 100 mg/kg) also pointed to the fact that strong antineoplastic effects of this drug in rat mammary carcinogenesis are independent from its effects on plasma lipid metabolism: atorvastatin in both concentrations in the diet did not change the serum levels of total cholesterol, and LDL-cholesterol, and triacylglycerols (Kubatka et al., 2011a) . Similarly in our study with rosuvastatin (25 and 250 mg/kg), changes of serum concentrations of total, LDL-and VLDL-cholesterol and triacylglycerols after rosuvastatin treatment did not significantly differ as compared to control animals (Kubatka et al., 2011b) . In another study, inhibitory effect of pravastatin against colon carcinogenesis in rats was not related to the cholesterol-lowering effect of this agent (Narisawa et al., 1996) . In the experiment of Lubet et al. (2009) , atorvastatin and lovastatin did not change serum triglyceride levels in rat mammary carcinogenesis. Contrary to these results, simvastatin (18 and 180 mg/kg) significantly decreased the levels of triacylglycerols and VLDLcholesterol in comparison with the controls in rat mammary carcinogenesis (Kubatka et al., 2011c) . Interestingly, atorvastatin (10 mg/kg), simvastatin (180 mg/kg), and rosuvastatin (250 mg/kg) significantly decreased serum HDLcholesterol in our experiments what is in contrast with the results in clinical trials, where the increase of this lipoprotein fraction ranged from 5 to 15% (Scandinavian simvastatin survival study, 1994; PROSPER study group, 2002).
Statins as cholesterol-lowering drugs are effective in guinea pigs or rabbits. The hypocholesterolemic effects of statins do not occur in rats because these animals have little or no LDL (Huff et Burnett, 1997) . Statins in rats affect VLDL assembly and secretion, and this is evidenced by a reduction in triacylglycerols rather than cholesterol because VLDL is rich of triacylglycerols. This mechanism of action is in accordance with our results in experiments where rats were treated by simvastatin or rosuvastatin, respectively. Simvastatin and rosuvastatin in higher doses decreased serum triacylglycerols by 30.5% or by 11% when compared to untreated controls (Kubatka et al., 2011a,b) . On the other hand, simvastatin and rosuvastatin did not change total cholesterol significantly in comparison with control animals. With the advent of new mouse models expressing specific human genes it is now possible to re-examine the effects of established hypolipidemic drugs and also new compounds with respect to site and mechanism of action. These model mice are now being screened for substances that lower plasma Lp (a) and cholesterol in the absence of LDL receptors (Krause and Princen, 1998) .
Several studies in rodents have shown protective effects of statins in experimental carcinogenesis. In our study, fluvastatin with significant antineoplastic effects on mammary carcinomas demonstrated evident adverse effects on plasma cholesterol and triacylglycerols in rats. Based on our results and results of other authors, we can conclude that rats are generally unresponsive to the hypocholesterolemic effects of statins observed in humans. It is proposed that new genetic mouse models may afford a more focused examination of new drugs and provide better prediction of the human response.
